TP53突变与高级别浆液性卵巢癌铂类耐药的相关性
本研究利用机构数据库对209例接受初始治疗的高级别浆液性卵巢癌患者进行二代测序,分析TP53突变不同分类方式(结构、功能、热点、致病性评分、免疫组化染色模式)与铂类耐药的关系。结果显示TP53热点突变、高致病性评分、功能获得性突变及免疫组化染色模式均与铂类耐药无显著关联。
要点
- TP53热点突变或高致病性评分与铂类耐药或难治性疾病无显著关联。
- TP53功能获得性突变与铂类耐药无显著关联,与既往研究结论相反。
- TP53突变的多样性可能过于复杂,简单模型难以显现效应。
核心结论
- TP53热点突变或高致病性评分与铂类耐药或难治性疾病无显著关联。
- 与既往研究相反,TP53功能获得性突变与铂类耐药无显著关联。
- 使用错义突变表型评分估计TP53功能获得效应与铂类耐药无显著关联。
- TP53突变的多样性可能过于复杂,简单模型难以显现效应,或铂类治疗反应可能独立于初始TP53突变。
研究设计与样本
- 研究利用本机构数据库获取接受初始治疗的高级别浆液性卵巢癌患者的二代测序数据,并回顾测序数据、人口学和临床信息。
- 共209例患者符合纳入标准。
- 主要分析结局为至复发或难治诊断的时间,并分析其与TP53突变不同分类方案(结构、功能、热点、致病性评分、免疫组化染色模式)的关联。
主要发现
- TP53突变是最常见的突变。
- TP53热点突变或高致病性评分与铂类反应无差异。
- TP53功能获得性突变的存在或TP53功能获得活性的测量与铂类耐药无关联。
- 免疫组化染色模式与预期的TP53蛋白功能相关,且与铂类耐药无关联。
临床怎么用
- 原文未据此给出推荐。
局限性
- TP53突变的多样性可能过于复杂,简单模型难以显现效应,或铂类治疗反应可能独立于初始TP53突变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Alterations in the tumor suppressor TP53 gene are the most common mutations in high grade serous ovarian carcinoma. The impact of TP53 mutations on clinical outcomes and platinum resistance is controversial. We sought to evaluate the genomic profile of high grade serous ovarian carcinoma and explore the association of TP53 mutations with platinum resistance. METHODS: Next generation sequencing data was obtained from our institutional database for patients with high grade serous ovarian carcinoma undergoing primary treatment. Sequencing data, demographic, and clinical information was reviewed. The primary outcome analyzed was time to recurrence or refractory diagnosis. Associations between the primary outcome and different classification schemes for TP53 mutations (structural, functional, hot spot, pathogenicity scores, immunohistochemical staining patterns) were performed. RESULTS: 209 patients met inclusion criteria. TP53 mutations were the most common mutation. There were no differences in platinum response with TP53 hotspot mutations or high pathogenicity scores. Presence of TP53 gain-of-function mutations or measure of TP53 gain-of function activity were not associated with platinum resistance. Immunohistochemical staining patterns correlated with expected TP53 protein function and were not associated with platinum resistance. CONCLUSIONS: TP53 hotspot mutations or high pathogenicity scores were not associated with platinum resistance or refractory disease. Contrary to prior studies, TP53 gain-of-function mutations were not associated with platinum resistance. Estimation of TP53 gain-of-function effect using missense mutation phenotype scores was not associated with platinum resistance. The polymorphic nature of TP53 mutations may be too complex to demonstrate effect using simple models, or response to platinum therapy may be independent of initiating TP53 mutation.
引用
- Montemorano L, Shultz ZB, Farooque A, et al. TP53 mutations and the association with platinum resistance in high grade serous ovarian carcinoma. Gynecol Oncol. 2024. PMID: 38555766. doi:10.1016/j.ygyno.2024.03.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。